Clinical Trial Update: Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC [Phase 2]

View source ↗

Summary

This update reports results from a Phase I/II trial evaluating lapatinib in combination with paclitaxel as first-line therapy for HER2-positive metastatic breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Taxol (paclitaxel)
• Tykerb (lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: COMPLETED | Results posted: 2014-09-19